Stockscreener 앱 받기
57.13
0.40%
0.23
시간 외 거래:
57.02
-0.11
-0.19%
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
A Congress Member Sold Up To $65K In Bristol-Myers Squibb Stock: Here's What You Need To Know - Benzinga
Bristol Myers Squibb Company $BMY Stake Lifted by Xponance LLC - MarketBeat
ICICI Prudential Asset Management Co Ltd Sells 39,000 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb’s AI Overhaul And Oncology Trials Shape Value Story - Yahoo Finance
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Takeda’s Zasocitinib Beats BMS’s Sotyktu In Moderate-To-Severe Plaque Psoriasis - Citeline News & Insights
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial - Reuters
Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue. - The Motley Fool
Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med - Benzinga
Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest - pharmaphorum
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test - Yahoo Finance
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Bristol Myers Squibb Links Brazil Lung Cancer Access To Long Term Story - Yahoo Finance
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Bristol-Myers Squibb Company (BMY) Featured in Citrini's Bullish Healthcare Basket - GuruFocus
BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 Study - Insider Monkey
Mariska Hargitay launches Bristol Myers Squibb's Myeloma Awareness Campaign - Indian Pharma Post
Inside Bristol Myers’ AI-powered procurement overhaul - CFO Dive
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.00% on Jun 8: A Full Analysis - TradingKey
Disciplined Core Equity Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Competitive approach better than restricting deals with China? - BioWorld News
Bristol Myers Squibb Tests CELMoD Research for Multiple Myeloma - Koran Manado
Mariska Hargitay Partners With Bristol Myers Squibb For Cancer Campaign - Koran Manado
Mariska Hargitay Honors Dad Mickey In Bristol Myers' Myeloma Campaign 06/08/2026 - MediaPost
Bristol Myers Squibb launches myeloma awareness campaign - Investing.com
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease - 巴士的報
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease – Company AnnouncementFT.com - Financial Times
Bristol-Myers Squibb (BMY) Investor Outlook: Analyzing a Promising 10.14% Upside and 4.40% Dividend Yield - DirectorsTalk Interviews
Israel Englander Heavily Boosts Bristol Myers Squibb Position - HarianBasis.co
Assessing Bristol Myers Squibb (BMY) Valuation After Fresh EU Opdivo Approval And New Phase 3 Oncology Data - simplywall.st
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know - Yahoo Finance
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Form 11-KAnnual report of employee stock purchase, savings and similar plans - ADVFN
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Loomis Sayles Strategic Income Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
How Investors May Respond To Bristol Myers Squibb (BMY) Winning EU Nod For First-Line Opdivo Regimen - Yahoo Finance
Bristol-Myers Squibb Co (BMY) Shares Surge 3.4% -- What GF Score of 78 Tells Investors - GuruFocus
Bristol Myers Squibb Adds New Late Stage Oncology Opportunity With Izalontamab - simplywall.st
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study - Yahoo Finance
Pharma’s ‘ugly sister’ is finally ready to offer beautiful returns - Investors' Chronicle
Bristol-Myers Squibb Outperforms Earnings Expectations Amid Market Turbulence - asatunews.co.id
Bristol-Myers Squibb Cancer Wins Test Investor Patience On Valuation - Yahoo Finance
Bristol Myers Squibb vs Pfizer Dividend Stock Comparison 2026News and Statistics - IndexBox
Painful psoriatic arthritis gets new oral option with FDA Sotyktu approval - Stock Titan
BMY Collaborates with Arcus Biosciences on Clinical Trial for Ca - GuruFocus
Radiation-emitting implant improves outcomes after brain cancer surgery - Reuters
Bristol-Myers Squibb stock (US1078421011): modest move as oncology data and institutional flows draw - AD HOC NEWS
Westpac Banking Corp Purchases 46,386 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate - PMLiVE
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now? - The Motley Fool
Bank of New York Mellon Corp Has $1.32 Billion Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Bristol-Myers Squibb Company stock (US0897961004): options activity spikes as new cancer trial data - AD HOC NEWS
BMY Stock Price, Quote & Chart | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Bristol Myers Squibb Target of Unusually High Options Trading (NYSE:BMY) - MarketBeat
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks - AOL.com
BMY: Positive Interim Results for Bristol Myers' Iza-bren in Can - GuruFocus
Bristol-Myers Squibb’s Italian Anticoagulant Study: Real-World Signals for BMY Investors - TipRanks
BMS-Hengrui deal strikes panic in Washington - BioWorld News
Bristol Myers Squibb: This Pullback Is A Gift For Long-Term Investors (NYSE:BMY) - Seeking Alpha
Bristol-Myers Squibb CoIzalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC - TradingView
Assessing Bristol Myers Squibb (BMY) Valuation As Shares Track Mixed Returns And Earnings Outlook - Yahoo Finance
ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice - Fierce Biotech
UBS raises Bristol-Myers Squibb stock price target on pipeline outlook - Investing.com
Big Pharma makes ‘creative effort’ to fold Chinese assets into pipelines - BioSpace
Bristol-Myers Squibb’s Stock Looks Cheap on the Surface, but Hidden Risks Lurk Beneath - NAI500
0.15%
0.22%
자본화:
|
볼륨(24시간):